PBA
AGIO icon

Paradigm Biocapital Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Paradigm Biocapital Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200,000
Closed -$8.03M – 31
2025
Q3 		$8.03M Buy
+200,000
New +$7.52M 0.23% 36

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Paradigm Biocapital Advisors's AGIO Position: Q4 2025 in Review

Paradigm Biocapital Advisors sold out of Agios Pharmaceuticals (AGIO) in Q4 2025, closing a stake of 2,673,555 shares — an estimated $107M sold.

Paradigm Biocapital Advisors first reported a position in AGIO in Q1 2024 and held it in 4 quarters. The position peaked at $107M in Q3 2025. 237 funds tracked by Wall St. Rank hold AGIO as of Q4 2025.

  • Paradigm Biocapital Advisors reported no remaining Agios Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,673,555 Agios Pharmaceuticals shares in Q4 2025, an estimated $107M.
  • Paradigm Biocapital Advisors first reported a position in Agios Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Paradigm Biocapital Advisors's Agios Pharmaceuticals position peaked at $107M in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.